advanced breast cancer
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2- negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
Overall survival ( OS ) results of the phase III MONALEESA-3 trial of postmenopausal patients ( pts ) with hormone receptor-positive ( HR+ ), human epidermal growth factor 2- negative ( HER2− ) advanced breast cancer ( ABC ) treated with fulvestrant ( FUL ) ± ribociclib ( RIB ) .